MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...
The FDA could approve the first blood test that can detect multiple cancers, around the end of the year, setting the stage ...
A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNA nanotechnology, ...
A multicancer early detection (MCED) test was developed and validated in the case-control Circulating Cell-free Genome Atlas (CCGA) study (ClinicalTrials.gov identifier: NCT02889978). Previous ...
Harbinger Health has grabbed $100 million in its latest funding round as the company reveals a new Resolve in its cancer detection work. Since coming out of stealth in 2021, Harbinger has been ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results